CryoLife, Inc. (CRY) Releases Quarterly Earnings Results, Meets Expectations
CryoLife, Inc. (NYSE:CRY) announced its quarterly earnings data on Monday. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08, Bloomberg Earnings reports. The business had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The company’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.13 earnings per share. CryoLife updated its FY17 guidance to $0.40-0.43 EPS.
Shares of CryoLife (NYSE CRY) opened at 20.10 on Tuesday. The firm has a market cap of $672.26 million, a price-to-earnings ratio of 60.91 and a beta of 0.92. CryoLife has a one year low of $14.02 and a one year high of $24.00. The stock has a 50 day moving average price of $21.74 and a 200 day moving average price of $19.61.
Several brokerages have recently weighed in on CRY. Zacks Investment Research lowered CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Lake Street Capital upped their price objective on CryoLife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. Canaccord Genuity restated a “buy” rating and issued a $25.00 price objective on shares of CryoLife in a report on Monday, October 9th. Finally, BidaskClub lowered CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. CryoLife currently has an average rating of “Hold” and a consensus target price of $23.63.
In other news, Director James Benson sold 2,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James P. Mackin sold 43,050 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total value of $950,974.50. Following the completion of the transaction, the chief executive officer now owns 398,399 shares in the company, valued at $8,800,633.91. The disclosure for this sale can be found here. Insiders sold a total of 171,050 shares of company stock worth $3,769,825 over the last quarter. Corporate insiders own 6.00% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.